All rights reserved. No part of this book may be reprinted or reproduced or utilised in any form or by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying and recording, or in any information storage or retrieval system, without permission in writing from the publishers. Enquiries in this regard should be directed to the British Psychological Society.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
March 2013: Some recommendations in sections 5.3.9, 5.4.9, 5.4.14, 5.4.19, 5.4.24 and 8.2 have been removed from this guideline by NICE. August 2018: Some recommendations have been updated to link to NICE topic pages.
The guideline on Antisocial Personality Disorder, commissioned by NICE and developed by the National Collaborating Centre for Mental Health, sets out clear, evidence- and consensus-based recommendations for staff working in health and social care and the criminal justice system on how to treat, manage and prevent antisocial personality disorder.
The NICE guideline takes the first comprehensive view of antisocial personality disorder and is an invaluable resource to enable professionals to improve the outcomes for people with the disorder, who often have significant impairments. Being able to prevent and properly manage antisocial personality disorder will also have considerable social implications.
This publication brings together all of the evidence that led to the recommendations in the NICE guideline, and draws on a wide literature, including evidence for the management of offending behaviour. It includes a review of interventions in children and young people with conduct disorder, which may prevent the development of antisocial personality disorder; risk assessment and management; organisation and experience of care; and a range of interventions for adults with antisocial personality disorder, including psychological interventions, treatment for comorbid disorders, therapeutic communities and pharmacological interventions. The book also contains a useful overview of antisocial personality disorder, including ethical considerations.
Contents
- GUIDELINE DEVELOPMENT GROUP MEMBERS
- 1. PREFACE
- 2. ANTISOCIAL PERSONALITY DISORDER
- 2.1. INTRODUCTION
- 2.2. THE DISORDER
- 2.3. AETIOLOGY
- 2.4. PRESENTATION IN HEALTHCARE AND OTHER SETTINGS
- 2.5. USE OF HEALTH SERVICE RESOURCES AND OTHER COSTS
- 2.6. TREATMENT AND MANAGEMENT IN THE NHS
- 2.7. THE DANGEROUS AND SEVERE PERSONALITY DISORDER INITIATIVE
- 2.8. THE ORGANISATION AND COORDINATION OF TREATMENT AND CARE
- 2.9. ASSESSMENT
- 2.10. ETHICAL CONSIDERATIONS IN ANTISOCIAL PERSONALITY DISORDER
- 3. METHODS USED TO DEVELOP THIS GUIDELINE
- 4. ORGANISATION AND EXPERIENCE OF CARE
- 5. INTERVENTIONS IN CHILDREN AND ADOLESCENTS FOR THE PREVENTION OF ANTISOCIAL PERSONALITY DISORDER
- 6. RISK ASSESSMENT AND MANAGEMENT
- 7. INTERVENTIONS FOR PEOPLE WITH ANTISOCIAL PERSONALITY DISORDER AND ASSOCIATED SYMPTOMS AND BEHAVIOURS
- 7.1. INTRODUCTION
- 7.2. PSYCHOLOGICAL INTERVENTIONS FOR ANTISOCIAL PERSONALITY DISORDER
- 7.3. TREATMENT OF COMORBID DISORDERS IN PEOPLE WITH ANTISOCIAL PERSONALITY DISORDER
- 7.4. THERAPEUTIC COMMUNITY INTERVENTIONS FOR PEOPLE WITH ANTISOCIAL PERSONALITY DISORDER AND ASSOCIATED SYMPTOMS AND BEHAVIOURS
- 7.5. PHARMACOLOGICAL INTERVENTIONS FOR ANTISOCIAL PERSONALITY DISORDER
- 7.6. RESEARCH RECOMMENDATIONS
- 8. SUMMARY OF RECOMMENDATIONS
- 9. APPENDICES
- APPENDIX 1. SCOPE FOR THE DEVELOPMENT OF THE CLINICAL GUIDELINE
- APPENDIX 2. DECLARATIONS OF INTERESTS BY GDG MEMBERS
- APPENDIX 3. SPECIAL ADVISERS TO THE GUIDELINE DEVELOPMENT GROUP
- APPENDIX 4. STAKEHOLDERS WHO RESPONDED TO EARLY REQUESTS FOR EVIDENCE
- APPENDIX 5. STAKEHOLDERS AND EXPERTS WHO SUBMITTED COMMENTS IN RESPONSE TO THE CONSULTATION DRAFT OF THE GUIDELINE
- APPENDIX 6. RESEARCHERS CONTACTED TO REQUEST INFORMATION ABOUT UNPUBLISHED OR SOON-TO-BE PUBLISHED STUDIES
- APPENDIX 7. ANALYTIC FRAMEWORK AND CLINICAL QUESTIONS
- APPENDIX 8. SEARCH STRATEGIES FOR THE IDENTIFICATION OF CLINICAL STUDIES
- APPENDIX 9. CLINICAL STUDY DATA EXTRACTION FORM
- APPENDIX 10. QUALITY CHECKLISTS FOR CLINICAL STUDIES AND REVIEWS
- APPENDIX 11. SEARCH STRATEGIES FOR THE IDENTIFICATION OF HEALTH ECONOMICS EVIDENCE
- APPENDIX 12. QUALITY CHECKLIST FOR ECONOMIC STUDIES
- APPENDIX 13. DATA EXTRACTION FORM FOR ECONOMIC STUDIES
- APPENDIX 14. EVIDENCE TABLES FOR ECONOMIC STUDIES
- APPENDIX 15. CHARACTERISTICS OF REVIEWED STUDIES
- APPENDIX 16. CLINICAL EVIDENCE FOREST PLOTS
- APPENDIX 17. STUDY CHARACTERISITCS OF RISK FACTORS FOR DEVELOPING ANTISOCIAL PERSONALITY DISORDER
- 10. REFERENCES
- 11. ABBREVIATIONS
The views presented in this book do not necessarily reflect those of the British Psychological Society, and the publishers are not responsible for any error of omission or fact. The British Psychological Society is a registered charity (no. 229642).
- Review Antisocial behaviour and conduct disorders in children and young people: recognition and management[ 2017]Review Antisocial behaviour and conduct disorders in children and young people: recognition and management. 2017 Apr
- Review Borderline Personality Disorder: Treatment and Management[ 2009]Review Borderline Personality Disorder: Treatment and ManagementNational Collaborating Centre for Mental Health (UK). 2009
- Review Depression: The Treatment and Management of Depression in Adults (Updated Edition)[ 2010]Review Depression: The Treatment and Management of Depression in Adults (Updated Edition)National Collaborating Centre for Mental Health (UK). 2010
- Review Drug Misuse: Opioid Detoxification[ 2008]Review Drug Misuse: Opioid DetoxificationNational Collaborating Centre for Mental Health (UK). 2008
- Review Depression in Adults with a Chronic Physical Health Problem: Treatment and Management[ 2010]Review Depression in Adults with a Chronic Physical Health Problem: Treatment and ManagementNational Collaborating Centre for Mental Health (UK). 2010
- Antisocial Personality DisorderAntisocial Personality Disorder
- ClinVar for Gene (Select 27245) (1136)ClinVar
- AHDC1[gene] (1136)ClinVar
- transcription factor Gibbin isoform X1 [Homo sapiens]transcription factor Gibbin isoform X1 [Homo sapiens]gi|2217266574|ref|XP_047273979.1|Protein
Your browsing activity is empty.
Activity recording is turned off.
See more...